BioWorld

March 1, 2010

IPO Activity Poised to Pop with Anthera, Aveo and Trius on Deck

It's been nearly a month since Ironwood Pharmaceuticals Inc. tested the biotech initial public offering waters, and now three more biotechs are queued up to price IPOs over the next three weeks. (BioWorld Today) Read More

HCV Combo Approach Keeping Partner Hopes Bright for Idenix

'Clear and Testable Hypothesis' on Pediatric Asthma's Roots

Amicus Adds $18.5M Publicly for Phase III Amigal Program

Collins: NIH Funding Boosts Economy, Spurs Job Growth

Move Over, Cerezyme; Shire's Vpriv Gets Official FDA Nod

Other News To Note

Vital Signs for March 1, 2010

Clinic Roundup

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists

BioWorld Science

Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.